Literature DB >> 2787464

The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat.

C Bolton1, R J Flower.   

Abstract

Lewis rats, sensitised for the autoimmune condition EAE received a range of doses of the steroid dexamethasone at various times post-inoculation in an attempt to modify the clinical course of the disease. Depending upon the dosing regime employed microgram quantities of the steroid were sufficient to significantly inhibit the clinical development of EAE and milligram doses of the drug completely suppressed the emergence of disease. Administration of the potent anti-glucocorticoid RU38486 to sensitised animals intensified the clinical course of EAE and reversed the steroid-induced inhibition of the disease. Furthermore, after the characteristic loss of neurological symptoms in rats receiving dexamethasone and RU38486, readministration of the anti-glucocorticoid resulted in clinical relapses in the majority of animals. The study emphasises the potent effects of exogenous, physiologically relevant doses of steroid on the course of EAE and, as a result of the observations made using RU38486, considers the role of endogenous steroids in the control of the disease in the rat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787464     DOI: 10.1016/0024-3205(89)90441-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE).

Authors:  Christopher Bolton; Janet Gates; Gavin Giovannoni
Journal:  Inflamm Res       Date:  2013-04-20       Impact factor: 4.575

2.  Effect of annexin-1 on experimental autoimmune encephalomyelitis (EAE) in the rat.

Authors:  I Huitinga; J Bauer; P J Strijbos; N J Rothwell; C D Dijkstra; F J Tilders
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

3.  A pharmacological study on the role of nitric oxide in the pathogenesis of experimental allergic encephalomyelitis.

Authors:  G S Scott; K I Williams; C Bolton
Journal:  Inflamm Res       Date:  1996-10       Impact factor: 4.575

4.  Development of specific antibody and in vivo response to antigen in different rat strains: effect of dexamethasone and importance of endogenous corticosteroids.

Authors:  S H Peers; G S Duncan; R J Flower
Journal:  Agents Actions       Date:  1993-07

5.  Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.

Authors:  C Perronne; Y Cohen; C Truffot-Pernot; J Grosset; J L Vildé; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

6.  Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.

Authors:  P Hambleton; S McMahon
Journal:  Agents Actions       Date:  1990-03

Review 7.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10

8.  Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis.

Authors:  Zeljka Miljković; Miljana Momcilović; Djordje Miljković; Marija Mostarica-Stojković
Journal:  J Neuroinflammation       Date:  2009-12-11       Impact factor: 8.322

9.  Neurovascular damage in experimental allergic encephalomyelitis: a target for pharmacological control.

Authors:  C Bolton
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

10.  Strain differences in thymic atrophy in rats immunized for EAE correlate with the clinical outcome of immunization.

Authors:  Mirjana Nacka-Aleksić; Marija Stojanović; Ivan Pilipović; Zorica Stojić-Vukanić; Duško Kosec; Gordana Leposavić
Journal:  PLoS One       Date:  2018-08-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.